Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 1
2022 2
2023 6
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Shrinkage versus fragmentation response in neoadjuvantly treated oesophageal adenocarcinoma: significant prognostic relevance.
Graham Martinez C, Kus Öztürk S, Al-Kaabi A, Valkema MJ, Bokhorst JM, Rosman C, Rütten H, Wauters CAP, Doukas M, van Lanschot JJ, Siersema PD, Nagtegaal ID, van der Post RS. Graham Martinez C, et al. Among authors: valkema mj. Histopathology. 2022 May;80(6):982-994. doi: 10.1111/his.14644. Epub 2022 Apr 6. Histopathology. 2022. PMID: 35352847 Free PMC article.
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon.
Valkema MJ, Spaander MCW, Boonstra JJ, van Dieren JM, Hazen WL, Erkelens GW, Holster IL, van der Linden A, van der Linde K, Oostenbrug LE, Quispel R, Schoon EJ, Siersema PD, Doukas M, Eyck BM, van der Wilk BJ, van der Sluis PC, Wijnhoven BPL, Lagarde SM, van Lanschot JJB. Valkema MJ, et al. Br J Surg. 2023 Sep 6;110(10):1381-1386. doi: 10.1093/bjs/znad211. Br J Surg. 2023. PMID: 37418342 Free PMC article.
18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ, de Lussanet de la Sablonière QG, Valkema R, Thomeer MGJ, Dwarkasing RS, Harteveld AA, Doukas M, Mostert B, van der Zijden CJ, van der Sluis PC, Lagarde SM, Wijnhoven BPL, Verburg FA, van Lanschot JJB. Valkema MJ, et al. Nucl Med Commun. 2024 Feb 1;45(2):128-138. doi: 10.1097/MNM.0000000000001793. Epub 2023 Nov 20. Nucl Med Commun. 2024. PMID: 37982560
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ, Beukinga RJ, Chatterjee A, Woodruff HC, van Klaveren D, Noordzij W, Valkema R, Bennink RJ, Roef MJ, Schreurs W, Doukas M, Lagarde SM, Wijnhoven BPL, Lambin P, Plukker JTM, van Lanschot JJB. Valkema MJ, et al. Nucl Med Commun. 2023 Aug 1;44(8):709-718. doi: 10.1097/MNM.0000000000001707. Epub 2023 May 3. Nucl Med Commun. 2023. PMID: 37132272 Free PMC article.
The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet-ring cells, and/or poorly cohesive cells.
Valkema MJ, Vos AM, van der Post RS, Ooms AH, Oudijk L, Eyck BM, Lagarde SM, Wijnhoven BP, Klarenbeek BR, Rosman C, van Lanschot JJB, Doukas M. Valkema MJ, et al. J Pathol Clin Res. 2023 Jul;9(4):322-335. doi: 10.1002/cjp2.321. Epub 2023 Mar 27. J Pathol Clin Res. 2023. PMID: 36971406 Free PMC article.
Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R. Valkema MJ, et al. J Nucl Med. 2019 Nov;60(11):1553-1559. doi: 10.2967/jnumed.118.224196. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877177 Free article. Clinical Trial.
A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.
van der Zijden CJ, Lagarde SM, Hermus M, Kranenburg LW, van Lanschot JJB, Mostert B, Nuyttens JJME, Oudijk L, van der Sluis PC, Spaander MCW, Valkema MJ, Valkema R, Wijnhoven BPL; SANO-2 study group. van der Zijden CJ, et al. Among authors: valkema mj. BMC Cancer. 2023 Apr 10;23(1):327. doi: 10.1186/s12885-023-10747-z. BMC Cancer. 2023. PMID: 37038138 Free PMC article.